BIORCHESTRA

About

BIORCHESTRA creates novel RNA-based therapeutics that will usher in a new era of treatment for neurodegenerative diseases.

Yusong,Taejon-jikhalsi,South Korea
1 - 10
https://www.biorchestra.com/

Highlights

Details

Last Funding Type: Series C
Last Funding Money Raised: $45M
Industries: Biopharma,Biotechnology,Health Care,Medical,Therapeutics
Founded date: Oct 18, 2016
Number Of Employee: 1 - 10
Operating Status: Active
Legal Name: Biorchestra Co., Ltd.
Also Known As: 바이오오케스트라

BIORCHESTRA is a biotech company that develops RNA-based therapeutics for treating neuroinflammatory diseases. They focus on changing the therapeutic paradigm from treating the symptoms to providing a fundamental cure for diseases. BIORCHESTRA develops neuroinflammatory disease therapeutics, with a particular emphasis on comprehensive patient care. BIORCHESTRA's complementary discovery platforms range from diagnosis to treatment monitoring.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

1

$45M

BIORCHESTRA has raised a total of $45M in funding over 2 rounds. Their latest funding was raised on Feb 22, 2022 from a Series C round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Feb 22, 2022	Series C	$45M	12	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

—

12

BIORCHESTRA is funded by 12 investors. GS Holdings and E&Venture Partners are the most recent investors.

Investor Name	Lead Investor	Funding Round
GS Holdings	—	Series C
E&Venture Partners	—	Series C
Widwin Investment	—	Series C
Chong Kun Dang Pharmaceutical Corp.	—	Series C
Dayli Partners	—	Series C
IMM Investment	—	Series C
LSK Investment	—	Series C
NH Investment & Securities	—	Series C
Quantum Ventures Korea	—	Series C
SBI Investment	—	Series C